Brokerages Set PepGen, Inc. (NASDAQ:PEPG) Target Price at $12.60

Shares of PepGen, Inc. (NASDAQ:PEPG) have been given a consensus rating of “Moderate Buy” by the six analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $12.60.

PEPG has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of PepGen in a report on Thursday, January 22nd. Guggenheim boosted their price objective on shares of PepGen from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Finally, Oppenheimer assumed coverage on shares of PepGen in a report on Wednesday, February 25th. They set an “outperform” rating and a $15.00 price objective for the company.

Institutional Trading of PepGen

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Rangeley Capital LLC raised its position in shares of PepGen by 133.3% during the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock valued at $39,000 after buying an additional 20,000 shares during the last quarter. Marshall Wace LLP acquired a new stake in PepGen during the second quarter worth about $44,000. Heights Capital Management Inc. acquired a new stake in PepGen during the third quarter worth about $46,000. Burkehill Global Management LP bought a new position in PepGen during the third quarter valued at about $46,000. Finally, Militia Capital Partners LP acquired a new position in PepGen in the 3rd quarter valued at approximately $72,000. 58.01% of the stock is currently owned by institutional investors and hedge funds.

PepGen Trading Down 1.5%

Shares of NASDAQ PEPG opened at $4.70 on Thursday. PepGen has a 52 week low of $0.88 and a 52 week high of $7.80. The stock has a market cap of $324.82 million, a price-to-earnings ratio of -1.95 and a beta of 1.87. The company’s 50-day moving average price is $5.67 and its 200 day moving average price is $5.05.

PepGen (NASDAQ:PEPG) last released its quarterly earnings data on Wednesday, March 4th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.13. As a group, research analysts expect that PepGen will post -2.73 earnings per share for the current year.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).